Trial · NCT07883395
Post-Market Clinical Follow-up of Intra-Articular Hyaluronic Acid in Hip Osteoarthritis
NCT07883395, Recruiting, Meiji Pharma Spain S.A.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Post-Market Clinical Follow-up of Intra-Articular Hyaluronic Acid in Hip Osteoarthritis. Trials, record NCT07883395. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07883395
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Post-Market Clinical Follow-up of Intra-Articular Hyaluronic Acid in Hip Osteoarthritis
- NCT number
- NCT07883395
- Status
- Recruiting
- Enrollment
- 40 participants, estimated
- Lead sponsor
- Meiji Pharma Spain S.A.
- Conditions
- Hip OA
- First posted
- 2026-10-20
- Last updated
- 2026-11-12
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change from Baseline in self-reported hip pain severityu as measured by Visual Analog Scale (VAS) Pain Score at 12 months | Baseline (pre-treatment), 3 months and 12 months post-treatment | Assessment of patient-reported hip pain severity on a VAS, consisting of a 100mm horizontal line ranging from 0 mm (no pain) to 100 mm (worst imaginable pain). Higher scores indicate greater pain intensity; a negative change score reflects pain reduction. |
| Secondary | Change from Baseline in hip osteoarthritis symptoms as measured by WOMAC Osteoarthritis Index Total Score | Baseline, Month 3, and Month 12 | Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) evaluating hip pain, stiffness, and physical function. Total score ranges from 0 to 96 points, where higher scores indicate worse symptom severity and greater physical disability. |
| Secondary | Change from Baseline in hip joint function as measured by Modified Harris Hip Score (mHHS) | Baseline, Month 3, and Month 12 | Clinician- and patient-assessed standardized scale evaluating hip joint pain, gait, daily activities, and range of motion. Total score ranges from 0 to 100 points, where higher scores indicate superior hip joint function. |
| Secondary | Change from Baseline in health-related quality of life as measured by the 12-Item Short Form Health Survey (SF-12) | Baseline and Month 12 | Assessment of physical and mental health-related quality of life dimensions using the 12-Item Short Form Health Survey (SF-12). Standardized scores range from 0 to 100 points, where higher scores represent better health-related quality of life. |
| Secondary | Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) | From baseline up to Month 12 | Percentage of participants experiencing adverse events and serious adverse events related or unrelated to intra-articular hyaluronic acid treatment throughout the follow-up period. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07883395
GET https://conductscience.org/api/trials/v1/NCT07883395/registered